Sentences with phrase «kite pharma»

For Current Kite Pharma Employees and Contractors: Please log onto your Internal Career Site to apply for this job Job Description We are seeking a highly...

Thirty - six percent of over 100 very ill lymphoma patients appeared disease - free six months after a single treatment, according to results released by the treatment's maker, Kite Pharma of Santa Monica, Calif..

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B - cell lymphomas.

Prior to joining Kite Pharma in 2011, Dr. Bot had technical leadership roles at MannKind Corporation and Alliance Pharmaceuticals.

«Ultimately, we needed 20 years to learn how to supercharge these cells to deliver anticancer activity,» says Arie Belldegrun, president and CEO of Kite Pharma in Santa Monica, California, which is assessing CAR T cells in six trials for B cell leukemia and lymphomas, and glioblastoma.

Gilead's deep dive into cellular therapeutics with the acquisitions of Kite Pharma and Cell Design Labs, along with the subsequent licensing deal with Sangamo Therapeutics to develop off - the - shelf cell therapies, is another key value creator that's arguably being under - appreciated by the market.

The SPDR S&P Biotech ETF (NYSEMKT: XBI) jumped 8.5 %, with components including Dyax (DYAX) rising 22 %, and Kite Pharma (KITE) posting a 21 % gain for the month.

Given the clinical trial results underpinning a new drug application for Kite Pharma's lead candidate, which the Food and Drug Administration is currently reviewing, I'd say there's a solid chance Gilead can squeeze out a return on its investment.

Kite Pharma's gains came following favorable attention for its experimental non-Hodgkin's lymphoma treatment KTE - C19.

Immunotherapy has been emerging from the backdrop of oncology research for years most notably from smaller companies such as Dendreon, Kite Pharma and Juno Therapeutics as leaders in the space.

Dendreon was first - to - market with its activated cellular therapy, Provenge ® in 2010 followed by a 7 year gap until Novartis» Kymriah ® was approved in August of 2017 which was shortly followed up by the approval of Kite Pharma's Yescata ® in November of 2017.

Kite Pharma is highly speculative since it is a clinical stage company that is not yet profitable.

Dr. Newman added that rival CAR T cell therapy developer Kite Pharma was still likelier to generate more revenue than Juno with KTE - C19, which last week completed patient enrollment in the Phase II portion of the ZUMA - 1 trial in patients with diffuse large B - cell lymphoma.

KITE KONNECT, KITE, and the KITE Logo are trademarks of Kite Pharma, Inc..

One of Juno's rivals, Kite Pharma, yesterday said it had completed its enrollment of 72 patients with diffuse large B - cell lymphoma in the Phase II portion of the ZUMA - 1 trial, designed to assess KTE - C19.

Gilead $ GILD has agreed to buy CAR - T pioneer Kite Pharma $ KITE — which is likely just months away from its first approval — for $ 11.9 billion in cash.

A riskier way to play immunotherapy is with Kite Pharma (KITE).

Kite Pharma $ KITE, newly bought out in a $ 12 billion deal by Gilead $ GILD, is coming in a close second with its own application for axicel.

YESCARTA, the YESCARTA Logo, KITE KONNECT, KITE, and the KITE Logo are trademarks of Kite Pharma, Inc..

(Reuters)- Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $ 12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.

One of the two companies that developed these treatments, Kite Pharma (now part of Gilead), was a venture - backed company.

Juno's setbacks contrast with the biologics license application planned this year by Novartis, and the rolling BLA in progress by Kite Pharma — which on Tuesday reported positive 6 - month trial data for its CAR T - cell lead candidate.

US - based pharmaceutical company Gilead Sciences entered the chimeric antigen receptor (CAR) T - cell therapy business through its acquisition of Kite Pharma, and Australian biopharma company CSL Behring acquired US - based Calimmune, a company that develops clinical - stage gene therapy solutions.

The race to become the first company with a chimeric antigen receptor T - cell (CAR - T) cancer therapy on the market has entered its final leg, and Kite Pharma now appears to have a big advantage.

Kite Pharma, Juno Therapeutics, and Bluebird Bio are among a growing group of biotech companies working with CAR - T.

Gilead's therapy (which the biotech giant acquired after snapping up developer Kite Pharma for just under $ 12 billion at the end of the summer) is approved for certain types of the blood cancer non-Hodgkin lymphoma.

Immuno - oncolocy has been the focus of Big Pharma and biotechs alike, with companies such as Merck (mrk), Bristol - Myers Squibb (bmy), Pfizer (pfe), Roche / Genentech, Juno (juno), Kite Pharma (kite), Novartis (nvs), and countless others pouring massive investments into the space (the Loncar ETF contains almost all of these companies).

Kite Pharma will race toward the regulatory finish line with its groundbreaking CAR - T cancer drug.

Merck and Bristol - Myers Squibb each have approved immunotherapy drugs, while Gilead Sciences announced Monday it plans to acquire Kite Pharma for $ 11.9 billion, just a few months before the FDA is expected to approve Kite's CAR - T drug for lymphoma on Nov. 29.

As we explained in our ASCO primer, pharma giants like Merck (mrk) and Bristol - Myers Squibb (bmy) and biotechs like Juno (juno) and Kite Pharma (kite) had a lot to prove through their clinical trial updates on experimental immunotherapies.

Gilead subsidiary Kite Pharma (which the biotech giant scooped up ahead of the FDA's approval for Yescarta, a treatment that reengineers patients» immune cells to fight cancer) will have access to Sangamo's platform technology, which could be used to create various types of cancer cell therapies.

Biotech giant Gilead Sciences is beefing up its cancer drug portfolio with a $ 11.9 billion deal to buy Kite Pharma, a company focused on a groundbreaking new class of treatments that turns the body's own immune cells into targeted blood cancer killers.

Gilead Sciences on Monday agreed to buy Kite Pharma for about $ 11.9 billion in cash, Dow Jones reported, citing sources.

Pete Najarian, «Fast Money Halftime Report» trader, discusses the Gilead - Kite Pharma $ 11.9 billion deal.

CAR - T treatments, including competing products from Novartis rivals Kite Pharma and Juno Therapeutics, come with the risk of potentially deadly side effects such as cytokine - release syndrome (CRS), in which a glut of T - cell - assisting cytokines can cause high fever, low blood pressure, and problems with lung oxygenation.

Kite Pharma, one of the companies chasing a new generation of cancer drugs called chimeric antigen receptor T - cell (CAR - T) therapies, announced a patient death in a clinical trial of its experimental KTE - C19.